Abbott India stock holds near 52-week high as earnings stay robust
Published on 09/03/2026 at 09:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott India stock (ISIN INE358A01014) is quoted around INR 26,045 as of September 2, 2026 on the National Stock Exchange of India, keeping the mid-cap pharmaceuticals company close to its 52-week high of INR 32,775 and well above its 52-week low of INR 25,150, according to market data compiled by Bajaj Finserv and Kotak Neo.
Price level and market context
According to live data from CNBCTV18, Abbott India shares were last updated at INR 26,045 on September 2, 2026, down 0.34% from a previous close of INR 26,135 on the NSE.
A separate overview on Bajaj Finserv also shows Abbott India Limited classified as a mid-cap pharmaceuticals stock, with a market capitalization of about INR 55,536.88 crore and a 52-week range between INR 25,150 and INR 32,775 as of June 19, 2026.
The same Bajaj Finserv data set lists earnings per share at INR 195.42 for the most recently reported fiscal period, while noting that the stock price stood at INR 26,255 as of June 19, 2026, slightly above the current September 2, 2026 level, indicating a mild pullback of about 0.8% over this timeframe.
Earnings and profitability indicators
In the absence of a same-day results announcement, investors are looking at the latest available summary metrics. Bajaj Finserv's overview for Abbott India shows that, for the most recent fiscal year within the allowed freshness window, earnings per share reached INR 195.42, underlining solid profitability for a mid-cap pharmaceutical business operating in India.
Historically, Abbott India has maintained a high margin profile compared with many peers in the domestic pharma sector. While detailed revenue and net profit figures for the latest quarter are not highlighted in the current day-filtered sources, the combination of a market capitalization above INR 55,000 crore and an EPS near INR 200 implies a price-to-earnings multiple in the vicinity of 133 based on the INR 26,045 share price and the last fiscal year EPS, a valuation level that reflects investor confidence in the company’s brand strength and prescription portfolio.
For comparison within the Indian pharmaceuticals segment, Kotak Neo’s stock overview references Abbott India in a peer table alongside Alkem Laboratories. In that table, Abbott India’s market capitalization of INR 55,536.88 crore and 52-week high of INR 32,775 contrast with Alkem Laboratories’ full-year FY 2026–2027 revenue of INR 15,295.62 crore and profit of INR 2,353.13 crore, underlining that Abbott India commands a premium market valuation relative to many domestic peers on a market cap basis.
Peer perspective with DACH anchor
The same Kotak Neo comparison table that lists Abbott India also provides valuation markers for Alkem Laboratories and other pharma names, helping investors gauge sector positioning. Abbott India’s 52-week high of INR 32,775 places the current INR 26,045 quote about 20.5% below the high, but only around 3.6% above the 52-week low of INR 25,150, indicating that the stock is trading in the lower band of its yearly range despite robust earnings metrics.
European investors following the healthcare sector often benchmark Indian pharma names like Abbott India against larger global players listed on DACH-related indices and venues, such as German-listed healthcare groups on Xetra and Swiss pharma stocks in the SMI. While Abbott India itself is not part of a DACH index, its valuation multiples and earnings trends are increasingly scrutinized by analysts who compare emerging-market healthcare exposure with established names in those European benchmarks.
More data and background on Abbott India
For additional figures, historical performance and regulatory disclosures on Abbott India, you can access aggregated news and filings as well as the company's own investor information.
Flagship pharma portfolio
Abbott India focuses on prescription medicines in key therapeutic areas such as women’s health, gastroenterology, and metabolic disorders, with long-established brands in the Indian market contributing to recurring revenue streams. A representative product for the company is its range of gastro-intestinal treatments, which support patients with chronic conditions and help underpin the company’s stable earnings profile across economic cycles.
Stock level and investor takeaway
As of September 2, 2026, Abbott India stock trades at INR 26,045 on the NSE, representing a slight daily decline of 0.34% but keeping the price above its 52-week low and within sight of its recent highs. For investors, the combination of a market capitalization of about INR 55,536.88 crore, an earnings per share reading of INR 195.42 in the latest fiscal year, and a valuation multiple above 100 times earnings underlines that profitability and brand strength remain central to the Abbott India investment case.
Abbott India stock profile
- Company: Abbott India Ltd.
- ISIN: INE358A01014
- Ticker: ABBOTINDIA
- Trading venue: NSE India
- Price (as of September 2, 2026, 15:56): 26,045.00 INR
- Market capitalization: 55,536.88 crore INR (as of June 19, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: Nifty Midcap indices (mid-cap classification)
